
NMD Pharma to present compelling preclinical data highlighting the potential of ClC-1 ion channel inhibition to improve ...
NMD Pharma to present compelling preclinical data highlighting the potential of ClC-1 ion channel inhibition to improve disease symptoms and progression in MuSK myasthenia gravis at the MGFA International Conference on Myasthenia and Related Disorders The …